Clinical trials

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Oncology #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Induced pluripotent stem cells in high-throughput cellular screening

Induced pluripotent stem cells in high-throughput cellular screening By Dr Carolyn E. Peluso With the failure rates of drug candidates continuing to present phenomenal costs to the pharmaceutical industry, this article discusses how newly emerging induced pluripotent stem cell (iPSC) technologies have the potential to be an… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical trials #Drug development #Enabling technologies #Gene therapy #High throughput screening #Imaging #In Silico Biology #Lead optimisation #Molecular medicine #Nanomedicine / nanotechnology #Patent Law #PCR #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics

Nanobioscience & Nanotechnology: The Future Of Personalised Medicine

Nanobioscience & Nanotechnology: The Future Of Personalised Medicine By Abhishek Gottipati, Joseph M. Sanders and Dr Scott A. Tenenbaum Nanotechnology has been more than a buzz word in the business world for a long time now and has been striding ahead, living up to the hype. Read More

#Exclusive Content

#Academic #Analysis #Animal models #Antimicrobials #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microbiome #Oncology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Therapeutics

Meeting the challenge of healthcare-associated infections with new antimicrobials: with a focus on Clostridium difficile

Meeting the challenge of healthcare-associated infections with new antimicrobials: with a focus on Clostridium difficile By Professor Peter Hawkey and Dr Katie Hardy Healthcare-associated infections (HCAI), previously known as hospital acquired infections (HAI), are defined as infections resulting from medical care or treatment in hospital. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #Imaging #Immunology #Lead discovery #Medicinal chemistry #Oncology #Pharmacogenomics #Pharmacology #Regenerative Medicine #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Challenges Of The Changing Drug Discovery Model

The Challenges Of The Changing Drug Discovery Model By Dr Mark Downs and Dr Tom Blackburn The drug development industry is restructuring worldwide. This brings different ways of working and new challenges. As the industry moves away from internally focused research to an external model, project management… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Oncology #Pathology #Pharmacology #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry

Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry By Dr Yi Gu and William Shi As the third-largest market for the pharmaceutical industry, the China/Asia region is becoming increasingly important. The AstraZeneca Innovation Center China (ICC) in Shanghai is perfectly positioned to benefit from close proximity to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Patent Law #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Innovate While Derisking Drug Development: Yes We Can!

Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Clinical specialities #Clinical trials #Drug development #Enabling technologies #High Content Screening #Imaging #Mass spectrometry / NMR #Oncology #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #System biology #Translational #Translational chemistry

In Vivo Imaging In Drug Development: Gamma Scintigraphy

In Vivo Imaging In Drug Development: Gamma Scintigraphy By Dr Alyson Connor Gamma scintigraphy is a non-invasive technique with applications in the development of drug products and the assessment of pharmacodynamic effects in humans. It enables the assessment of critical performance parameters that in vitro techniques attempt,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biobanking #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Metabolomics #Molecular medicine #Oncology #Patent Law #Precision medicine #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation.

The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation. By Chris Molloy A leading ballet conductor (1) recently told me of courses which he runs for senior business leaders. He allows them to conduct an orchestra: first, very strictly, with close… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #Imaging #Immunology #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology

Current and Emerging Trends In Immunogenicity Research

Current and Emerging Trends In Immunogenicity Research In November 2011 Drug Discovery World hosted a collegial style roundtable discussion on the present and emerging developments in this fundamental area of drug discovery and development. The participants are drawn from the biopharmaceutical, biotechnology and vendor community. Although somewhat… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #Immunology #Lead discovery #Pharmacology #Preclinical #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

From Outsourced To Open: The continuing evolution of the drug discovery business model

From Outsourced To Open: The continuing evolution of the drug discovery business model Dr Mary Canady One doesn’t have to look far to find that the large pharmaceutical business model has many market forces working against it, such as patent expirations, dwindling pipelines, and reduced R&D productivity. However,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #Imaging #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Pathology #Regenerative Medicine #Regulatory #RNA #Stem cells #Translational #Translational chemistry

Ontario as a Life Sciences Powerhouse

Ontario as a Life Sciences Powerhouse By Michael Stewart Around the world, competition between life sciences companies is fierce. And so is the competition between jurisdictions wanting to attract the good paying jobs, innovative spirit and R&D that comes along with this important economic sector. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation

The Apocalyptic Horsemen of Drug Discovery and Development

The Apocalyptic Horsemen of Drug Discovery and Development By Dr Gary J. Keil The pharmaceutical industry should consider an evolutionary disease management approach based on homeostasis, irreversibility, biological alinearity, pseudo-N-of-1 health and disease states and narrative medicine best practices in order to help secure a successful drug… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biochemistry #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Oncology #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Therapeutics

SMAC Mimetics: a new class of targeted agents that activate apoptotic cell death and block pro-survival signalling in cancer cells

SMAC Mimetics: a new class of targeted agents that activate apoptotic cell death and block pro-survival signalling in cancer cells By Dr Mark A. McKinlay SMAC mimetics are a new class of targeted drugs being developed for the treatment of solid tumours and hematologic cancers. SMAC mimetics… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Stem Cell Technology – Delivering the promise

By Dr Aaron Heifetz The promise of stem cell technology as a tool for drug discovery, drug development and as a therapeutic modality is no longer in the future but part of contemporary healthcare. The speed which stem cells have… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Biomarkers #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Oncology #Pathology #Protein chemistry / Proteomics #RNA #Sequencing #Stem cells #Target validation #Therapeutics #Toxicology

Targeting Target Cancer Metabolism – What is fuelling the resurgence?

Targeting Target Cancer Metabolism – What is fuelling the resurgence? By Dr Neil P. Jones Targeting the metabolic pathways of cancer is a hot topic for drug discovery. The central dogma is that cancers have a higher demand for metabolic inputs to aid proliferation and survival and… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Automation / robotics #Biochemistry #Business #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #High Content Screening #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #RNA

Combining chemists expertise and a computer’s advanced capabilities to generate good ideas.

Combining chemists expertise and a computer’s advanced capabilities to generate good ideas. By Dr Matthew Segall, Edmund Champness, Dr Chris Leeding, Dr Ryan Lilien, Dr Ramgopal Mettu and Dr Brian Stevens Drug One of the defining challenges of drug discovery is the need to make complex decisions regarding… Read More

#Archive